Risks of Opioids in ST-Elevation Myocardial Infarction: A Review

被引：5

作者：

Tavenier, Anne Henrieke ^{[1
]}

Hermanides, Renicus Suffridus ^{[1
]}

Ottervanger, Jan Paul ^{[1
]}

Ter Horst, Peter Gerrit Johannes ^{[2
]}

Kedhi, Elvin ^{[1
]}

van't Hof, Adriaan W. J. ^{[3
,4
]}

机构：

[1] Isala, Dept Cardiol, Dr van Heesweg 2, NL-8025 AB Zwolle, Netherlands

[2] Isala, Dept Clin Pharm, Zwolle, Netherlands

[3] Maastricht Univ, Dept Cardiol, Med Ctr, Maastricht, Netherlands

[4] Zuyderland Med Ctr, Dept Cardiol, Heerlen, Netherlands

来源：

DRUG SAFETY | 2018年 / 41卷 / 12期

关键词：

PERCUTANEOUS CORONARY INTERVENTION; PLATELET INHIBITION; MORPHINE USE; SEGMENT ELEVATION; TABLETS; PAIN; ACETAMINOPHEN; REMIFENTANIL; AGGREGATION; ASSOCIATION;

D O I：

10.1007/s40264-018-0710-y

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

Although opioids are recommended and frequently used in the acute phase of ST-elevation myocardial infarction (STEMI), their use is accompanied by serious side effects. In particular, gastrointestinal adverse effects may disturb absorption of essential oral medication like platelet inhibitors. This may cause suboptimal platelet inhibition and increased risk of acute stent thrombosis. Some clinical studies have already demonstrated these negative results. Alternative strategies to optimize platelet inhibition and pain relief in STEMI are being investigated. Clinicians should become more aware of the potential side effects of opioids in STEMI.

引用

页码：1303 / 1308

页数：6